

## Income statement

### Three months ended 30th September 2010

	Results before major restructuring £m	Major restructuring £m	Total £m	Results before major restructuring \$m	Major restructuring \$m	Total \$m
<b>TURNOVER</b>	<b>6,813</b>	-	<b>6,813</b>	<b>10,636</b>	-	<b>10,636</b>
Cost of sales	(1,875)	(31)	(1,906)	(2,924)	(49)	(2,973)
Gross profit	4,938	(31)	4,907	7,712	(49)	7,663
Selling, general and administration	(1,956)	(84)	(2,040)	(3,073)	(133)	(3,206)
Research and development	(948)	(56)	(1,004)	(1,480)	(91)	(1,571)
Other operating income	95	-	95	150	-	150
<b>OPERATING PROFIT</b>	<b>2,129</b>	<b>(171)</b>	<b>1,958</b>	<b>3,309</b>	<b>(273)</b>	<b>3,036</b>
Finance income	22	-	22	34	-	34
Finance expense	(196)	(1)	(197)	(306)	(2)	(308)
Share of after tax profits of joint ventures and associates	16	-	16	25	-	25
<b>PROFIT BEFORE TAXATION</b>	<b>1,971</b>	<b>(172)</b>	<b>1,799</b>	<b>3,062</b>	<b>(275)</b>	<b>2,787</b>
Taxation	(480)	24	(456)	(748)	39	(709)
<b>PROFIT AFTER TAXATION FOR THE PERIOD</b>	<b>1,491</b>	<b>(148)</b>	<b>1,343</b>	<b>2,314</b>	<b>(236)</b>	<b>2,078</b>
Profit attributable to non-controlling interests	55	-	55	85	-	85
Profit attributable to shareholders	1,436	(148)	1,288	2,229	(236)	1,993
	1,491	(148)	1,343	2,314	(236)	2,078
<b>EARNINGS PER SHARE</b>	<b>28.2p</b>		<b>25.3p</b>	<b>44.0p</b>		<b>39.5p</b>
Diluted earnings per share	28.0p		25.1p	43.7p		39.2p

US dollar amounts shown above are a convenience translation of the sterling amounts.

## Income statement

### Nine months ended 30th September 2010

	Results before major restructuring £m	Major restructuring £m	Total £m	Results before major restructuring \$m	Major restructuring \$m	Total \$m
<b>TURNOVER</b>	<b>21,195</b>	-	<b>21,195</b>	<b>32,640</b>	-	<b>32,640</b>
Cost of sales	(5,425)	(90)	(5,515)	(8,355)	(139)	(8,494)
Gross profit	15,770	(90)	15,680	24,285	(139)	24,146
Selling, general and administration	(8,099)	(493)	(8,592)	(12,472)	(759)	(13,232)
Research and development	(2,881)	(479)	(3,360)	(4,437)	(738)	(5,174)
Other operating income	375	-	375	578	-	578
<b>OPERATING PROFIT</b>	<b>5,165</b>	<b>(1,062)</b>	<b>4,103</b>	<b>7,954</b>	<b>(1,636)</b>	<b>6,318</b>
Finance income	58	-	58	89	-	89
Finance expense	(588)	(3)	(591)	(906)	(5)	(911)
Share of after tax profits of associates and joint ventures	63	-	63	97	-	97
<b>PROFIT BEFORE TAXATION</b>	<b>4,698</b>	<b>(1,065)</b>	<b>3,633</b>	<b>7,234</b>	<b>(1,641)</b>	<b>5,593</b>
Taxation	(1,410)	263	(1,147)	(2,171)	405	(1,766)
<b>PROFIT AFTER TAXATION FOR THE PERIOD</b>	<b>3,288</b>	<b>(802)</b>	<b>2,486</b>	<b>5,063</b>	<b>(1,236)</b>	<b>3,827</b>
Profit attributable to non-controlling interests	162	-	162	249	-	249
Profit attributable to shareholders	3,126	(802)	2,324	4,814	(1,236)	3,578
	3,288	(802)	2,486	5,063	(1,236)	(3,827)
<b>EARNINGS PER SHARE</b>	<b>61.5p</b>		<b>45.7p</b>	<b>94.7¢</b>		<b>70.4¢</b>
Diluted earnings per share	61.0p		45.3p	93.9¢		69.8¢

US dollar amounts shown above are a convenience translation of the sterling amounts.

## Turnover

### Pharmaceuticals - Three months ended 30th September 2010

	Total £m	USA £m	Europe £m	Emerging Markets £m	ROW £m	Total \$m	USA \$m	Europe \$m	Emerging Markets \$m	ROW \$m
<b>Respiratory</b>	<b>1,726</b>	<b>846</b>	<b>488</b>	<b>145</b>	<b>247</b>	<b>2,694</b>	<b>1,320</b>	<b>763</b>	<b>226</b>	<b>385</b>
<i>Avamys/Veramyst</i>	40	15	10	8	7	62	23	16	13	10
<i>Flixonase/Flonase</i>	32	8	8	9	7	51	13	13	14	11
<i>Flixotide/Flovent</i>	187	105	33	10	39	292	164	52	15	61
<i>Seretide/Advair</i>	1,243	649	370	77	147	1,939	1,012	578	120	229
<i>Serevent</i>	48	16	24	1	7	75	26	37	1	11
<i>Ventolin</i>	130	50	32	27	21	202	77	50	42	33
<i>Zyrtec</i>	19	-	-	4	15	30	-	-	6	24
<b>Anti-virals</b>	<b>218</b>	<b>57</b>	<b>24</b>	<b>56</b>	<b>81</b>	<b>342</b>	<b>91</b>	<b>38</b>	<b>87</b>	<b>126</b>
<i>Hepsera</i>	32	-	-	16	16	50	-	-	25	25
<i>Relenza</i>	18	13	2	1	2	28	21	3	1	3
<i>Valtrex</i>	95	27	14	7	47	149	44	21	11	73
<i>Zeffix</i>	55	3	7	32	13	86	4	11	50	21
<b>Central nervous system</b>	<b>436</b>	<b>124</b>	<b>131</b>	<b>63</b>	<b>118</b>	<b>680</b>	<b>193</b>	<b>205</b>	<b>98</b>	<b>184</b>
<i>Imigran/Imitrex</i>	53	18	22	1	12	82	28	34	1	19
<i>Lamictal</i>	131	70	35	15	11	204	109	55	23	17
<i>Requip</i>	58	13	32	1	12	90	20	50	1	19
<i>Seroxat/Paxil</i>	115	5	19	19	72	179	8	30	29	112
<i>Treximet</i>	13	13	-	-	-	21	21	-	-	-
<i>Wellbutrin</i>	18	4	10	3	1	28	6	15	5	2
<b>Cardiovascular and urogenital</b>	<b>650</b>	<b>409</b>	<b>144</b>	<b>34</b>	<b>63</b>	<b>1,013</b>	<b>637</b>	<b>225</b>	<b>53</b>	<b>98</b>
<i>Arixtra</i>	72	43	22	3	4	112	67	34	5	6
<i>Avodart</i>	156	87	41	8	20	243	135	64	13	31
<i>Coreg</i>	44	43	-	-	1	68	66	-	-	2
<i>Fraxiparine</i>	54	-	34	15	5	84	-	53	23	8
<i>Lovaza</i>	138	137	-	-	1	215	213	-	-	2
<i>Vesicare</i>	28	27	-	-	1	44	42	-	-	2
<i>Volibris</i>	11	-	10	1	-	17	-	15	2	-
<b>Metabolic</b>	<b>125</b>	<b>32</b>	<b>37</b>	<b>12</b>	<b>44</b>	<b>197</b>	<b>51</b>	<b>58</b>	<b>19</b>	<b>69</b>
<i>Avandia products</i>	70	33	20	2	15	111	52	32	3	24
<i>Boniva/Boniva</i>	17	-	13	1	3	26	-	21	1	4
<b>Anti-bacterials</b>	<b>333</b>	<b>14</b>	<b>121</b>	<b>151</b>	<b>47</b>	<b>520</b>	<b>22</b>	<b>189</b>	<b>236</b>	<b>73</b>
<i>Augmentin</i>	153	1	55	74	23	239	2	86	115	36
<b>Oncology and emesis</b>	<b>172</b>	<b>89</b>	<b>49</b>	<b>17</b>	<b>17</b>	<b>269</b>	<b>139</b>	<b>77</b>	<b>26</b>	<b>27</b>
<i>Arzerra</i>	9	8	1	-	-	14	12	2	-	-
<i>Hycamtin</i>	35	21	11	2	1	55	33	18	3	1
<i>Promacta</i>	7	6	1	-	-	11	10	1	-	-
<i>Tyverb/Tykerb</i>	58	18	23	9	8	90	28	36	14	12
<i>Votrient</i>	11	9	1	-	1	17	14	2	-	1
<b>Vaccines</b>	<b>982</b>	<b>278</b>	<b>310</b>	<b>216</b>	<b>178</b>	<b>1,535</b>	<b>431</b>	<b>487</b>	<b>337</b>	<b>280</b>
<i>Boostrix</i>	59	41	12	2	4	91	63	18	4	6
<i>Cervarix</i>	48	4	11	8	25	76	7	17	13	39
<i>Fluarix, FluLaval</i>	167	81	50	19	17	257	124	77	29	27
<i>Flu Pandemic</i>	58	1	2	6	49	99	2	7	11	79
<i>Hepatitis</i>	189	97	55	20	17	294	150	86	31	27
<i>Infanrix, Pediarix</i>	168	38	96	16	18	262	59	150	25	28
<i>Rotarix</i>	52	17	8	20	7	81	26	13	31	11
<i>Synflorix</i>	90	-	9	74	7	139	-	14	114	11
<b>Dermatologicals</b>	<b>272</b>	<b>93</b>	<b>59</b>	<b>73</b>	<b>47</b>	<b>424</b>	<b>145</b>	<b>92</b>	<b>114</b>	<b>73</b>
<i>Bactroban</i>	33	14	7	8	4	52	22	11	12	7
<i>Dermovate</i>	18	-	5	7	6	28	-	8	11	9
<i>Duac</i>	33	20	5	3	5	51	31	8	4	8
<i>Soriatane</i>	19	19	-	-	-	29	29	-	-	-
<i>Zovirax</i>	31	8	6	6	11	49	12	10	10	17
<b>Other</b>	<b>238</b>	<b>8</b>	<b>65</b>	<b>106</b>	<b>59</b>	<b>372</b>	<b>13</b>	<b>102</b>	<b>165</b>	<b>92</b>
	<b>5,152</b>	<b>1,950</b>	<b>1,428</b>	<b>873</b>	<b>901</b>	<b>8,046</b>	<b>3,042</b>	<b>2,236</b>	<b>1,361</b>	<b>1,407</b>
<b>ViiV Healthcare (HIV)</b>	<b>401</b>	<b>162</b>	<b>136</b>	<b>59</b>	<b>44</b>	<b>625</b>	<b>253</b>	<b>213</b>	<b>91</b>	<b>68</b>
<i>Combivir</i>	96	36	26	24	10	150	56	41	37	16
<i>Epivir</i>	31	10	9	7	5	48	15	14	11	8
<i>Epzicom/Kivexa</i>	138	50	57	12	19	215	78	89	19	29
<i>Lexiva</i>	39	19	13	7	-	61	29	20	11	1
<i>Selzentry</i>	20	8	10	-	2	31	12	16	-	3
<i>Trizivir</i>	38	19	15	3	1	59	30	24	4	1
	<b>5,553</b>					<b>8,671</b>				

Pharmaceutical turnover includes co-promotion income. US dollar amounts shown above are a convenience translation of the sterling amounts.

## Turnover

### Pharmaceuticals - Nine months ended 30th September 2010

	Total £m	USA £m	Europe £m	Emerging Markets £m	ROW £m	Total \$m	USA \$m	Europe \$m	Emerging Markets \$m	ROW \$m
<b>Respiratory</b>	<b>5,321</b>	<b>2,519</b>	<b>1,592</b>	<b>454</b>	<b>756</b>	<b>8,194</b>	<b>3,879</b>	<b>2,452</b>	<b>699</b>	<b>1,164</b>
<i>Avamys/Veramyst</i>	143	52	44	22	25	220	80	68	34	38
<i>Flixonase/Flonase</i>	127	32	30	28	37	196	50	46	43	57
<i>Flixotide/Flovent</i>	584	313	117	36	118	899	482	180	55	182
<i>Seretide/Advair</i>	3,793	1,934	1,185	243	431	5,841	2,978	1,825	374	664
<i>Serevent</i>	151	49	74	2	26	233	76	114	3	40
<i>Ventolin</i>	380	130	104	82	64	585	200	160	126	99
<i>Zyrtec</i>	59	-	-	10	49	91	-	-	15	76
<b>Anti-virals</b>	<b>862</b>	<b>329</b>	<b>85</b>	<b>162</b>	<b>286</b>	<b>1,327</b>	<b>507</b>	<b>131</b>	<b>249</b>	<b>440</b>
<i>Hepsera</i>	95	-	-	43	52	146	-	-	66	80
<i>Relenza</i>	110	48	6	2	54	169	74	9	3	83
<i>Valtrex</i>	436	228	53	20	135	671	351	81	31	208
<i>Zeffix</i>	169	10	20	97	42	260	15	31	149	65
<b>Central nervous system</b>	<b>1,303</b>	<b>391</b>	<b>408</b>	<b>161</b>	<b>343</b>	<b>2,007</b>	<b>602</b>	<b>629</b>	<b>248</b>	<b>528</b>
<i>Imigran/Imitrex</i>	162	60	65	4	33	249	92	100	6	51
<i>Lamictal</i>	374	191	109	41	33	576	294	168	63	51
<i>Requip</i>	173	34	104	2	33	266	52	160	3	51
<i>Seroxat/Paxil</i>	354	27	63	54	210	545	42	97	83	323
<i>Treximet</i>	42	41	-	-	1	65	63	-	-	2
<i>Wellbutrin</i>	59	17	28	9	5	91	26	43	14	8
<b>Cardiovascular and urogenital</b>	<b>1,874</b>	<b>1,149</b>	<b>451</b>	<b>98</b>	<b>176</b>	<b>2,886</b>	<b>1,769</b>	<b>695</b>	<b>151</b>	<b>271</b>
<i>Arixtra</i>	221	128	75	7	11	340	197	115	11	17
<i>Avodart</i>	452	251	125	24	52	696	386	193	37	80
<i>Coreg</i>	130	129	-	-	1	200	198	-	-	2
<i>Fraxiparine</i>	167	-	116	40	11	257	-	179	61	17
<i>Lovaza</i>	383	382	-	-	1	590	588	-	-	2
<i>Vesicare</i>	83	82	-	-	1	128	126	-	-	2
<i>Volibris</i>	30	-	27	1	2	46	-	41	2	3
<b>Metabolic</b>	<b>568</b>	<b>198</b>	<b>153</b>	<b>74</b>	<b>143</b>	<b>875</b>	<b>305</b>	<b>236</b>	<b>114</b>	<b>220</b>
<i>Avandia products</i>	391	197	92	39	63	602	303	142	60	97
<i>Bonviva/Boniva</i>	60	-	50	2	8	92	-	77	3	12
<b>Anti-bacterials</b>	<b>1,026</b>	<b>59</b>	<b>383</b>	<b>450</b>	<b>134</b>	<b>1,580</b>	<b>91</b>	<b>590</b>	<b>693</b>	<b>206</b>
<i>Augmentin</i>	457	11	171	213	62	704	17	263	328	96
<b>Oncology and emesis</b>	<b>516</b>	<b>275</b>	<b>146</b>	<b>45</b>	<b>50</b>	<b>795</b>	<b>424</b>	<b>225</b>	<b>69</b>	<b>77</b>
<i>Arzerra</i>	22	20	1	-	1	34	30	2	-	2
<i>Hycamtin</i>	115	69	36	6	4	177	106	56	9	6
<i>Promacta</i>	21	19	2	-	-	32	29	3	-	-
<i>Tyverb/Tykerb</i>	167	53	69	21	24	257	82	106	32	37
<i>Votrient</i>	24	22	1	-	1	37	34	2	-	1
<b>Vaccines</b>	<b>3,332</b>	<b>592</b>	<b>1,288</b>	<b>667</b>	<b>785</b>	<b>5,131</b>	<b>912</b>	<b>1,983</b>	<b>1,027</b>	<b>1,209</b>
<i>Boostrix</i>	132	82	32	5	13	203	126	49	8	20
<i>Cervarix</i>	175	12	91	18	54	270	19	140	28	83
<i>Fluarix, FluLaval</i>	172	82	50	20	20	265	126	77	31	31
<i>Flu Pandemic</i>	1,031	1	398	201	431	1,588	2	613	309	664
<i>Hepatitis</i>	556	251	179	65	61	856	386	276	100	94
<i>Infanrix, Pediarix</i>	510	110	309	37	54	785	169	476	57	83
<i>Rotarix</i>	156	53	29	57	17	240	81	45	88	26
<i>Synflorix</i>	173	-	35	114	24	266	-	54	175	37
<b>Dermatologicals</b>	<b>799</b>	<b>264</b>	<b>184</b>	<b>204</b>	<b>147</b>	<b>1,230</b>	<b>407</b>	<b>283</b>	<b>314</b>	<b>226</b>
<i>Bactroban</i>	90	39	20	21	10	139	60	31	32	16
<i>Dermovate</i>	52	-	14	19	19	80	-	22	29	29
<i>Duac</i>	89	52	17	8	12	137	80	26	12	19
<i>Soriatane</i>	54	54	-	-	-	83	83	-	-	-
<i>Zovirax</i>	113	39	20	20	34	174	60	31	31	52
<b>Other</b>	<b>688</b>	<b>18</b>	<b>211</b>	<b>272</b>	<b>187</b>	<b>1,060</b>	<b>28</b>	<b>325</b>	<b>419</b>	<b>288</b>
	<b>16,289</b>	<b>5,794</b>	<b>4,901</b>	<b>2,587</b>	<b>3,007</b>	<b>25,085</b>	<b>8,924</b>	<b>7,549</b>	<b>3,983</b>	<b>4,629</b>
<b>ViiV Healthcare (HIV)</b>	<b>1,163</b>	<b>497</b>	<b>440</b>	<b>96</b>	<b>130</b>	<b>1,791</b>	<b>765</b>	<b>678</b>	<b>148</b>	<b>200</b>
<i>Combivir</i>	264	109	89	37	29	407	168	137	57	45
<i>Epivir</i>	86	30	29	12	15	132	46	45	18	23
<i>Epzicom/Kivexa</i>	409	155	182	20	52	630	239	280	31	80
<i>Lexiva</i>	119	60	41	11	7	183	92	63	17	11
<i>Selzentry</i>	58	25	30	1	2	89	38	46	2	3
<i>Trizivir</i>	112	57	46	4	5	172	88	71	6	7
	<b>17,452</b>					<b>26,876</b>				

Pharmaceutical turnover includes co-promotion income. US dollar amounts shown above are a convenience translation of the sterling amounts.

## Turnover

### Consumer Healthcare Three months ended 30th September 2010

	Total £m	Total \$m
Over-the-counter medicines	601	938
Oral healthcare	400	624
Nutritional healthcare	259	403
	<u>1,260</u>	<u>1,965</u>

	Total £m	Total \$m
USA	249	388
Europe	491	766
Rest of World	520	811
	<u>1,260</u>	<u>1,965</u>

## Turnover

### Consumer Healthcare Nine months ended 30th September 2010

	Total £m	Total \$m
Over-the-counter medicines	1,811	2,789
Oral healthcare	1,191	1,834
Nutritional healthcare	741	1,141
	<u>3,743</u>	<u>5,764</u>

	Total £m	Total \$m
USA	758	1,167
Europe	1,455	2,241
Rest of World	1,530	2,356
	<u>3,743</u>	<u>5,764</u>

## Balance sheet

	30th September 2010 £m	30th September 2010 \$m
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	9,152	14,460
Goodwill	3,484	5,505
Other intangible assets	8,369	13,223
Investments in associates and joint ventures	1,062	1,678
Other investments	560	885
Deferred tax assets	2,510	3,966
Derivative financial instruments	125	197
Other non-current assets	593	937
<b>Total non-current assets</b>	<b>25,855</b>	<b>40,851</b>
<b>Current assets</b>		
Inventories	4,074	6,437
Current tax recoverable	48	76
Trade and other receivables	5,986	9,458
Derivative financial instruments	215	340
Liquid investments	216	341
Cash and cash equivalents	6,229	9,842
Assets held for sale	25	39
<b>Total current assets</b>	<b>16,793</b>	<b>26,533</b>
<b>TOTAL ASSETS</b>	<b>42,648</b>	<b>67,384</b>
<b>LIABILITIES</b>		
<b>Current liabilities</b>		
Short-term borrowings	(386)	(610)
Trade and other payables	(6,806)	(10,753)
Derivative financial instruments	(231)	(365)
Current tax payable	(1,172)	(1,852)
Short-term provisions	(2,648)	(4,184)
<b>Total current liabilities</b>	<b>(11,243)</b>	<b>(17,764)</b>
<b>Non-current liabilities</b>		
Long-term borrowings	(14,851)	(23,465)
Deferred tax liabilities	(706)	(1,115)
Pensions and other post-employment benefits	(3,385)	(5,348)
Other provisions	(1,263)	(1,996)
Derivative financial instruments	(7)	(11)
Other non-current liabilities	(580)	(916)
<b>Total non-current liabilities</b>	<b>(20,792)</b>	<b>(32,851)</b>
<b>TOTAL LIABILITIES</b>	<b>(32,035)</b>	<b>(50,615)</b>
<b>NET ASSETS</b>	<b>10,613</b>	<b>16,769</b>
<b>EQUITY</b>		
Share capital	1,417	2,239
Share premium account	1,400	2,212
Retained earnings	5,839	9,226
Other reserves	1,153	1,822
<b>Shareholders' equity</b>	<b>9,809</b>	<b>15,499</b>
Non-controlling interests	804	1,270
<b>TOTAL EQUITY</b>	<b>10,613</b>	<b>16,769</b>

US dollar amounts shown above are a convenience transaction of the sterling amounts using the period end rate of £1/\$1.58.